Following Shaanxi Jinye Science Technology And Education Group Co.Ltd(000812) (000812) and Yunnan Xiyi Industrial Co.Ltd(002265) (002265), A-Shares reproduce the new “demon shares” – Aba Chemicals Corporation(300261) (300261).
On December 28, Aba Chemicals Corporation(300261) reaped another 20% limit rise, which has increased by 160% in the past seven trading days. Since November, Aba Chemicals Corporation(300261) has soared 274%.
On the 28th, Aba Chemicals Corporation(300261) announced that the company’s share price belongs to serious abnormal fluctuation. The relevant situation will be verified and the trading will be suspended from the 29th. Meanwhile, Aba Chemicals Corporation(300261) replied to the letter of concern of Shenzhen stock exchange that the company has not signed any cooperation agreement with Pfizer and has no cooperative relationship with Pfizer.
Aba Chemicals Corporation(300261) also said that a2w (Maltese subsidiary a2wpharma Ltd.) The main structure of CBD (cannabinoid) medical product production workshop has been basically completed, equipment installation and application for GMP certification are under way, and no CBD medical products have been produced and sold this year, which will not bring any sales revenue and profit to the company in 2021 and 2022.
share price soared 160%, suspension verification
Aba Chemicals Corporation(300261) is a high-end product customizer in China’s fine chemical industry, mainly engaged in the R & D, production and sales of pharmaceutical intermediates and pesticide intermediates. The company’s customized R & D and production business (cdmo) mainly provides customized R & D and production services of pesticide intermediates and pharmaceutical intermediates for world-class pesticide and pharmaceutical customers. As of the first half of the year, pesticide intermediate business accounted for 73.55% of Aba Chemicals Corporation(300261) revenue, pharmaceutical intermediate business accounted for 13.60% of the company’s revenue, and environmental protection products, other businesses and special chemicals accounted for less than 6%.
Recently, two news triggered a sharp rise in the company’s share price. One is Aba Chemicals Corporation(300261) recently said that the main structure of CBD medical product production workshop under Malta subsidiary has been basically completed. At present, equipment installation and application for GMP certification are under way. Cannabinoid is a pure natural component extracted from cannabis plant.
Second, it is rumored that Aba Chemicals Corporation(300261) has a cooperative relationship with Pfizer, mainly pointing out that Aba Chemicals Corporation(300261) supplies carlon anhydride and its derivatives to Pfizer.
since December 20, Aba Chemicals Corporation(300261) share price has started the soaring mode. As of December 28, the company’s share price has increased by 160% as a whole. During the seven trading days, the company’s share price has increased by 20% in four trading days, and the company has also issued four announcements of abnormal stock price fluctuations.
On December 28, Aba Chemicals Corporation(300261) latest announced that the company’s share price belongs to serious abnormal fluctuation from December 20 to December 28. The company will verify the serious abnormal fluctuation of stock trading. The trading of the company’s shares will be suspended since the opening of the market on December 29, 2021 and resumed after the disclosure of the verification announcement.
According to the dragon and tiger list, 27.4081 million institutional seats were bought in large quantities on December 22. On the 23rd, the famous niusan and top hot money “Xu Liusheng” bought 10.8501 million. On the 27th, the famous hot money “Fang Xinxia” and “Shanghai Liyang road” bought 37.209 million and 25.6999 million respectively.
According to the disclosure of Shenzhen Stock Exchange, Aba Chemicals Corporation(300261) increased by 159.62% from December 20 to December 28. During the period of serious abnormal increase, natural persons bought 7.897 billion yuan, accounting for 77.14%; Among them, small and medium-sized investors bought 3.771 billion yuan, accounting for 36.84%. Institutions bought 2.34 billion yuan, accounting for 22.86%.
clarify two major messages
The recent sharp rise in share prices has also attracted the attention of regulators. On December 23, the management department of gem company of Shenzhen Stock Exchange issued a concern letter to Aba Chemicals Corporation(300261) , asking whether the company indirectly provided carlon anhydride products to Pfizer and the impact of relevant businesses on performance; At the same time, a2wpharma Ltd., a subsidiary of the company in Malta, is required.. Production and commissioning of CBD (cannabinoid) products and their impact on the company’s future performance.
On December 28, Aba Chemicals Corporation(300261) synchronously replied to the letter of concern of Shenzhen Stock Exchange, clarifying the above issues in detail.
Aba Chemicals Corporation(300261) said that as of the reply date of this letter of concern, the company had not signed any cooperation agreement with Pfizer, had no cooperative relationship with Pfizer, and did not supply carlon anhydride and its derivatives to Pfizer. As of the reply date of this letter of concern, the sales revenue of the company’s carbonic anhydride and its derivatives is 27.073 million yuan, accounting for about 1% – 2% of the company’s total operating revenue in 2021, which is relatively small. It is not expected to have a significant impact on the company’s performance in 2021 and 2022. If the downstream demand of the company’s carbonic anhydride and its derivatives decreases in the future, or the supply of other manufacturers in the industry increases significantly, the product supply may exceed the demand, which may have an adverse impact on the company’s operation and performance.
In addition, as of the reply date of this letter of concern, the main structure of a2w CBD medical product production workshop has been basically completed, equipment installation and application for GMP certification are under way, and no CBD medical products have been produced and sold this year. Affected by the epidemic in Europe, the company expects that the CBD medical products of a2w will be officially put into operation in the first quarter of 2023, and will not bring any sales revenue and profit contribution to the company in 2021 and 2022, and will not have a significant impact on the financial and operating conditions of the company in 2021 and 2022. If the overseas epidemic continues to spread, the construction progress of a2w production workshop may be less than expected; The GMP certification process of a2w is uncertain, which may affect the production progress of CBD medical products; If the supply and demand situation of CBD market changes in the future, it will have an adverse impact on the project; A2w is a newly established overseas company, which may face market risks, changes in national policies and other risks in the actual operation process.
In addition, Aba Chemicals Corporation(300261) also reminds investors that up to now, the company’s operation has not changed significantly. From November 1, 2021 to December 27, 2021, the company’s stock price increased by about 211.31%, which was significantly higher than the change degree of the company’s fundamentals and did not match the company’s current fundamentals. Please pay attention to the risks.
According to the statistics of the reporter of securities times · e company, from November 1 to December 28, Aba Chemicals Corporation(300261) share price rose 274% in total. In the first three quarters of this year, Aba Chemicals Corporation(300261) achieved an operating revenue of 1.604 billion yuan, a year-on-year increase of 7.08%, a net profit of 151 million yuan, a year-on-year increase of 23.03%, and a year-on-year decrease of 16.88%.
it can not be ignored that, according to the announcement on December 1, Aba Chemicals Corporation(300261) Wang Xinya, one of the actual controllers, reduced his holdings of 19 million shares through block trading on November 30, accounting for 1.97% of the total share capital of the company. The average reduction price was 7.24 yuan / share, with a total cash out of 138 million yuan.
In addition, Aba Chemicals Corporation(300261) also received the decision on administrative punishment issued by the CSRC for disclosing suspected misleading statements on the interactive platform.
(E company)
